RxDoctor Payments Data

Shamekia Nwafor

Optometrist · Carencro, LANPI 1063791077

Payments from drug & device makers

$2,753in general payments, 2019–2025

Across 145 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$951
  • Sun Pharmaceutical Industries Inc.$372
  • Alcon$329
  • Mallinckrodt Hospital Products Inc.$245
  • Novartis$228
  • Ivantis, Inc$127
  • plus $500 from 14 others

What the payments were for

  • Food & beverage$2,63496%
  • Education$1004%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,753 in reported general payments places this provider in the 70th percentile of 500 optometrist providers in Louisiana.

See all optometrist providers in Louisiana

Medicare billing

Part B allowed, 2024
$49,987
Medicare patients
294
Services billed
677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine14$7,738
LumiganBimatoprost12$5,515
Brimonidine Tartrate23$3,417
Travoprost22$3,128
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$2,757
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat47$834
Latanoprost55$739
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha25$240
Timolol Maleate18$216
ErythromycinErythromycin Base11$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$951$5,51512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 500 optometrist providers in Louisiana.

Other optometrist in Carencro

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →